Literature DB >> 9305562

Inhaled nitric oxide: clinical applications, indications, and toxicology.

E Troncy1, M Francoeur, G Blaise.   

Abstract

PURPOSE: Although the analogy of nitric oxide (NO) to Endothelium-derived Relaxing Factor remains controversial, medical use of exogenous NO gas by inhalation has grown exponentially. This review presents the mechanisms of action of inhaled NO in pulmonary hypertension, hypoxaemia, inflammation and oedema, as well as its therapeutic and diagnostic indications with emphasis on acute respiratory distress syndrome (ARDS) and toxicology. SOURCE: Two medical databases (Current Contents, Medline) were searched for citations containing the above-mentioned key words to December 1996. Moreover, many presentations in congresses such as 4th International Meeting of Biology of Nitric Oxide, 52nd and 53rd Annual Meeting of Canadian Anaesthetists' Society or 10th Annual Meeting of European Association of Cardiothoracic Anaesthesiologists were used. PRINCIPAL
FINDINGS: Inhaled NO is now recognized as an invaluable tool in neonatal and paediatric critical care, and for heart/lung surgery. Other clinical applications in adults, such as chronic obstructive pulmonary disease and ARDS, require a cautious approach. The inhaled NO therapy is fairly inexpensive, but it would seem that it is not indicated for everybody with regards to the paradigm of its efficiency and potential toxicity. The recent discovery of its anti-inflammatory and extrapulmonary effects open new horizons for future applications.
CONCLUSION: Clinical use of inhaled NO was mostly reported in case series, properly designed clinical trials must now be performed to establish its real therapeutic role. These trials would permit adequate selection of the cardiopulmonary disorders, and subsequently the patients that would maximally benefit from inhaled NO therapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9305562     DOI: 10.1007/BF03011970

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  8 in total

1.  Nitric Oxide-Releasing Cyclodextrins.

Authors:  Haibao Jin; Lei Yang; Mona Jasmine R Ahonen; Mark H Schoenfisch
Journal:  J Am Chem Soc       Date:  2018-10-16       Impact factor: 15.419

2.  Increased resting heart rate with pollutants in a population based study.

Authors:  Jean-Bernard Ruidavets; Sylvie Cassadou; Maxime Cournot; Vincent Bataille; Mariam Meybeck; Jean Ferrières
Journal:  J Epidemiol Community Health       Date:  2005-08       Impact factor: 3.710

Review 3.  Pharmacotherapy of acute lung injury and acute respiratory distress syndrome.

Authors:  Krishnan Raghavendran; Gloria S Pryhuber; Patricia R Chess; Bruce A Davidson; Paul R Knight; Robert H Notter
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

Review 4.  What is the clinical significance of pulmonary hypertension in acute respiratory distress syndrome? A review.

Authors:  P S Lai; C Mita; B T Thompson
Journal:  Minerva Anestesiol       Date:  2013-10-31       Impact factor: 3.051

5.  Inhaled nitric oxide and the risk of renal dysfunction in patients with acute respiratory distress syndrome: a propensity-matched cohort study.

Authors:  Sheng-Yuan Ruan; Hon-Yen Wu; Hsien-Ho Lin; Huey-Dong Wu; Chong-Jen Yu; Mei-Shu Lai
Journal:  Crit Care       Date:  2016-11-30       Impact factor: 9.097

Review 6.  Arterial pulmonary hypertension in noncardiac intensive care unit.

Authors:  Mykola V Tsapenko; Arseniy V Tsapenko; Thomas Bo Comfere; Girish K Mour; Sunil V Mankad; Ognjen Gajic
Journal:  Vasc Health Risk Manag       Date:  2008

7.  A randomized clinical trial testing the anti-inflammatory effects of preemptive inhaled nitric oxide in human liver transplantation.

Authors:  John D Lang; Alvin B Smith; Angela Brandon; Kelley M Bradley; Yuliang Liu; Wei Li; D Ralph Crowe; Nirag C Jhala; Richard C Cross; Luc Frenette; Kenneth Martay; Youri L Vater; Alexander A Vitin; Gregory A Dembo; Derek A Dubay; J Steven Bynon; Jeff M Szychowski; Jorge D Reyes; Jeffrey B Halldorson; Stephen C Rayhill; Andre A Dick; Ramasamy Bakthavatsalam; Jared Brandenberger; Jo Ann Broeckel-Elrod; Laura Sissons-Ross; Terry Jordan; Lucinda Y Chen; Arunotai Siriussawakul; Devin E Eckhoff; Rakesh P Patel
Journal:  PLoS One       Date:  2014-02-12       Impact factor: 3.240

8.  Tadalafil: Protective Action against the Development of Multiple Organ Failure Syndrome.

Authors:  Granville G de Oliveira; Samer A H de Oliveira; Paulo Henrique H Botelho; Marcos Aurelio Barboza de Oliveira; Ka Bian; Ferid Murad
Journal:  Braz J Cardiovasc Surg       Date:  2017 Jul-Aug
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.